Dupixent EOE denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Dupixent for Eosinophilic Esophagitis as Duplicate Therapy

A duplicate-therapy denial for Dupixent (dupilumab) in eosinophilic esophagitis (EoE) means UnitedHealthcare identified another agent in your current regimen that it considers therapeutically overlapping. For EoE, this most commonly occurs when a patient is already using swallowed topical corticosteroids (such as swallowed fluticasone or budesonide formulations), an elimination diet protocol documented as active treatment, or potentially another biologic. UHC's system flags these as potentially duplicative with an IL-4/IL-13 pathway inhibitor.

This denial is typically appealable because dupilumab has a distinct mechanism — it targets systemic type-2 inflammation at the IL-4 receptor alpha level — which is biologically different from topical corticosteroid action within the esophageal lumen, and different from dietary modification. A well-constructed appeal will make this mechanistic distinction explicit.

## Federal Appeal Rights

• ERISA §503 (employer-sponsored plans) entitles you to a full-and-fair internal review and the specific clinical criteria applied to the denial.
• ACA §2719 provides independent external IRO review if the internal appeal is denied — at no cost to you.
• Internal appeal: typically 180 days from the denial notice.
• External review: typically 4 months from final internal denial.
• Expedited review: request in writing with prescriber support if delay would seriously jeopardize your health.

## What to Gather

1. Diagnosis documentation — endoscopy and biopsy reports confirming EoE diagnosis, current eosinophil counts per high-power field from pathology, symptom burden notes (dysphagia frequency and severity, food impaction history). 2. Current medication and treatment list with dates — every agent UHC may consider duplicative, with start dates and a clear clinical description of each agent's mechanism and role. 3. Prescriber medical-necessity and non-duplication letter — your gastroenterologist should explain (a) why the current regimen does not address the systemic IL-4/IL-13 driven inflammation that dupilumab targets, (b) why continued or additional topical therapy is insufficient for your disease burden, and (c) the distinct clinical role of dupilumab. 4. FDA-approved prescribing label for dupilumab in EoE — reference the indication and mechanism of action sections to demonstrate the biologically distinct target. 5. UHC's coverage policy for dupilumab in EoE — map each "not duplicate" criterion to a specific chart entry.

## Criteria-Mapping Structure

| UHC Duplicate-Therapy Criterion | Supporting Evidence | |---|---| | Distinct mechanism from current therapy | Prescriber letter explaining systemic IL-4/IL-13 blockade vs. topical action | | Current therapy inadequate for disease burden | Biopsy eosinophil counts, symptom diary, endoscopy findings | | Dupilumab not therapeutically equivalent to existing agent | FDA label mechanism-of-action section; prescriber attestation |

IRO reviewers — who evaluate independently of UHC — are well-positioned to assess mechanistic distinctions in biologic therapy. Submit the complete package with the prescriber letter at the center.